~7 spots leftby Jun 2026

MDMA for Borderline Personality Disorder

(MDMA in BPD Trial)

Recruiting in Palo Alto (17 mi)
SK
Overseen bySarah K Fineberg, MD, PhD
Age: 18 - 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Yale University
No Placebo Group
Prior Safety Data
Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.

Research Team

SK

Sarah K Fineberg, MD, PhD

Principal Investigator

Yale University

Eligibility Criteria

This trial is for adults with Borderline Personality Disorder. Specific eligibility criteria are not provided, but typically participants must meet diagnostic criteria for the condition being studied and may need to pass certain health checks.

Inclusion Criteria

Willing to remain overnight at the study site after each experimental session if recommended
Able to provide written informed consent according to Yale IRB guidelines
Able to read and write English proficiently
See 11 more

Exclusion Criteria

History of bipolar disorder, schizophrenia, schizoaffective disorder, or currently exhibiting psychotic features
My heart often beats faster than 90 beats per minute.
I have a history of serious medical or neurological illness.
See 10 more

Treatment Details

Interventions

  • MDMA (Other)
Trial OverviewThe study is testing the effects of MDMA on social cognition in individuals with Borderline Personality Disorder. Social cognition involves how people process, store, and apply information about others and social situations.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Open-Label MDMAExperimental Treatment1 Intervention
Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).

Find a Clinic Near You

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials
1,963
Recruited
3,046,000+
Nancy J. Brown profile image

Nancy J. Brown

Yale University

Chief Medical Officer since 2020

MD from Yale School of Medicine

Peter Salovey profile image

Peter Salovey

Yale University

Chief Executive Officer since 2013

PhD in Psychology from Yale University

Connecticut Mental Health Center

Collaborator

Trials
2
Recruited
160+